Libmyris®
ACTIVE PRINCIPLE:
Adalimumab
INDICATION:
Rheumatoid Arthritis
Juvenile rheumatoid arthritis
Ankylosing spondylitis
Psoriasic arthritis
Psoriasis
Hidradenitis suppurativa
Crohn's disease
Ulcerative colitis
Uveitis
DATE:
12/11/2021
STATUS:
Authorized